Evidence map›Paper›PMID 38457030›Full record

ArticleClinical and experimental nephrology2024

Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.

Ayumi Yoshifuji, Masataro Toda, Emi Oyama, Tetsuo Nakayama, Setsuko Mise-Omata, Kan Kikuchi, Mamoru Yoshizawa, Naohiko Kato, Haruki Wakai, Kiyoto Koibuchi and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ayumi Yoshifuji *Department of Nephrology, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-Ku, Tokyo, 108-0073, Japan. ayutsuranaide@keio.jp.ORCID http://orcid.org/0000-0001-8246-8675
Masataro Toda *Department of Nephrology, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-Ku, Tokyo, 108-0073, Japan.
Emi OyamaDepartment of Nephrology, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-Ku, Tokyo, 108-0073, Japan.
Tetsuo NakayamaLaboratory of Viral Infection, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan.
Setsuko Mise-OmataDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Kan KikuchiDivision of Nephrology, Shimoochiai Clinic, Tokyo, Japan.
Mamoru YoshizawaDivision of Nephrology, Yoshizawa Clinic, Saitama, Japan.
Naohiko KatoDivision of Nephrology, Shinagawa-Jin Clinic, Tokyo, Japan.
Haruki WakaiDivision of Nephrology, Shinagawa Garden Clinic, Tokyo, Japan.
Kiyoto KoibuchiDepartment of Nephrology and Dialysis, Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.
Kohkichi MorimotoApheresis and Dialysis Center, Keio University School of Medicine, Tokyo, Japan.
Yoshifumi UwaminoDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Ho NamkoongDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Ayako ShibataDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Kaoru WakabayashiClinical Research Center, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
Motoko FujinoDepartment of Pediatrics, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
Motoaki KomatsuDepartment of Nephrology, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-Ku, Tokyo, 108-0073, Japan.
Naoki MochizukiDepartment of Nursing, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
Norihiko KondoKonan-No-Sato, Tokyo, Japan.
Akihiko YoshimuraDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Naoki HasegawaDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Munekazu RyuzakiDepartment of Nephrology, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-Ku, Tokyo, 108-0073, Japan. ryuzaki-m@saichu.jp.

Funding

Japan Agency for Medical Research and Development 21fk0108469h0001Japan Agency for Medical Research and Development JP20fk0108283Japan Agency for Medical Research and Development JP20fk0108415Japan Agency for Medical Research and Development JP20fk0108452Japan Agency for Medical Research and Development JP21fk0108468Japan Agency for Medical Research and Development JP21fk0108469Japan Agency for Medical Research and Development JP21ym0126022Japan Agency for Medical Research and Development JP22gm1110009Japan Agency for Medical Research and Development JP22zf0127003Japan Society for the Promotion of Science 21H05044Japan Society for the Promotion of Science 22K1944
6 · The paper itself

Abstract

backgroundDialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity.

methodsParticipants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group.

resultsBooster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group.

conclusionsHD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.

Indexed as

Antibodies, ViralBNT162 VaccineCOVID-19Immunity, HumoralImmunization, SecondaryRenal DialysisAdultAgedCOVID-19 VaccinesCytokinesEast Asian PeopleFemaleHumansImmunity, CellularImmunoglobulin GJapanAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesCytokinesImmunoglobulin GBNT162b2 vaccineBooster vaccineCOVID-19HemodialysisHypoimmunityPeritoneal dialysis

Identifiers

PMID38457030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.